Literature DB >> 27101747

Comment on: 'Central retinal vein occlusion: modifying current treatment protocols'.

D Călugăru1, M Călugăru1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27101747      PMCID： PMC5129862          DOI： 10.1038/eye.2016.83

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  7 in total

1.  Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.

Authors:  T D Papakostas; L Lim; T van Zyl; J B Miller; B S Modjtahedi; C M Andreoli; D Wu; L H Young; I K Kim; D G Vavvas; D D Esmaili; D Husain; D Eliott; L A Kim
Journal:  Eye (Lond)       Date:  2015-10-09       Impact factor: 3.775

Review 2.  Central retinal vein occlusion: modifying current treatment protocols.

Authors:  M Ashraf; A A R Souka; R P Singh
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

3.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

4.  Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Sharon Solomon; Ingrid Zimmer-Galler; Akrit Sodhi; Elia Duh; Howard Ying; Adam Wenick; Syed Mahmood Shah; Diana V Do; Quan D Nguyen; Saleema Kherani; Raafay Sophie
Journal:  Ophthalmology       Date:  2015-05-09       Impact factor: 12.079

5.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

6.  Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves.

Authors:  Marlene D Wang; Karen W Jeng-Miller; Henry L Feng; Jonathan L Prenner; Howard F Fine; Sumit P Shah
Journal:  Br J Ophthalmol       Date:  2015-12-30       Impact factor: 4.638

7.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

Authors:  Jean-François Korobelnik; Frank G Holz; Johann Roider; Yuichiro Ogura; Christian Simader; Ursula Schmidt-Erfurth; Katrin Lorenz; Miki Honda; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079
  7 in total
  2 in total

1.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-21       Impact factor: 3.117

Review 2.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.